GD2-PSMA-CD276 4SCAR-T

**GD2-PSMA-CD276 4SCAR-T** is an engineered, fourth-generation chimeric antigen receptor T-cell therapy being evaluated for relapsed or refractory neuroblastoma. The product uses CARs directed against disialoganglioside GD2, prostate-specific membrane antigen, and CD276 antigen, with CD28, CD137, CD27, and CD3-zeta intracellular signaling domains to promote T-cell activation and antitumor cytotoxicity. It also incorporates an inducible caspase-9 safety switch intended to enable elimination of the infused cells with AP1903 if serious toxicity occurs. The program is sponsored by Shenzhen Geno-Immune Medical Institute in a Phase I/II neuroblastoma study. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-gd2-psma-cd276-4scar-expressing-t-cells))

Other names

anti-GD2/anti-PSMA/anti-CD276 4SCAR T cellsanti-GD2/PSMA/CD276 4SCAR-expressing T cellsGD2/PSMA/CD276 4SCAR T cellsmulti-4SCAR-T cellsmulti4SCAR-T cellsmulti 4SCAR-T cells